The Virtual Lab of AI agents designs new SARS-CoV-2 nanobodies.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40730228.
- Also identified by DOI 10.1038/s41586-025-09442-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Science frequently benefits from teams of interdisciplinary researchers<sup>1-3</sup>, but many scientists do not have easy access to experts from multiple fields<sup>4,5</sup>. Although large language models (LLMs) have shown an impressive ability to aid researchers across diverse domains, their uses have been largely limited to answering specific scientific questions rather than performing open-ended research<sup>6-11</sup>. Here we expand the capabilities of LLMs for science by introducing the Virtual Lab, an artificial intelligence (AI)-human research collaboration to perform sophisticated, interdisciplinary science research. The Virtual Lab consists of an LLM Principal Investigator agent guiding a team of LLM scientist agents through a series of research meetings, with a human researcher providing high-level feedback. We applied the Virtual Lab to design nanobody binders to recent variants of SARS-CoV-2. The Virtual Lab created a novel computational nanobody design pipeline that incorporates the protein language model ESM, the protein folding model AlphaFold-Multimer and the computational biology software Rosetta and designed 92 new nanobodies. Experimental validation reveals a range of functional nanobodies with promising binding profiles across SARS-CoV-2 variants. In particular, two new nanobodies exhibit improved binding to the recent JN.1 or KP.3 variants<sup>12,13</sup> while maintaining strong binding to the ancestral viral spike protein, suggesting that these are suitable candidates for further investigation. This work demonstrates how the Virtual Lab can rapidly make an impactful, real-world scientific discovery.
Medical subject headings
- Single-Domain Antibodies
- SARS-CoV-2
- Artificial Intelligence
- User-Computer Interface